Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).

Lomitapide is a microsomal triglyceride transfer protein inhibitor designed to inhibit the formation of chylomicrons and very low-density lipoprotein.

“You are going to die young.” The first time I heard those six words, they were jarring. And I chuckle when I hear them.

Approval expands indication of JUXTAPID® to include children 2 years of age and older with HoFHThis announcement was made during the week of Rare ...

In a traditional observational analysis, associations of LDL-C with incident chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and all-cause mortality were U-shaped or ...

Compared with placebo, obicetrapib lowered LDL-C by 33% at day 84 (P .0001). Topline results were announced from a phase 3 trial evaluating obicetrapib, an investigational low dose cholesterol ester ...

In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...

Please provide your email address to receive an email when new articles are posted on . “Patients with hyperlipidemia and established cerebrovascular disease are at an increased risk of future strokes ...

In another study of dyslipidemic patients not treated with hypolipidemic drugs (baseline examination), a very good correlation between LDL-C and apoB (r = 0.903; p < 0.001) was found. [66] In spite of ...

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant ...

There is a lot of misinformation about cholesterol, making people believe that eggs are bad or that exercising can do away with a bad diet. However, this may be far from the truth. A neurologist ...